Stimulation of vitamin A1 acid signaling by the HIV protease inhibitor indinavir

Biochemical Pharmacology

Volumn 59, Issue 9, 2000, Pages 1063-1068

  Lenhard, James M ^a   Weiel, James E ^a   Paulik, Mark A ^a   Furfine, Eric S ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Adipogenesis; Dyslipidemia; Indinavir; Lipodystrophy; Retinoic acid; Toxicity

Indexed keywords

3,5 DI TERT BUTYL 4' CHALCONECARBOXYLIC ACID; 4 [2 [5,6 DIHYDRO 5,5 DIMETHYL 8 (4 METHYLPHENYL) 2 NAPHTHYL]ETHYNYL]BENZOIC ACID; ALKALINE PHOSPHATASE; AMPRENAVIR; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RETINOIC ACID; RETINOIC ACID BINDING PROTEIN; RETINOIC ACID RECEPTOR; RETINOID; RITONAVIR; SAQUINAVIR;

ADIPOCYTE; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL LINE; CELL STRUCTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID STORAGE; MESENCHYME; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; HIV PROTEASE INHIBITORS; INDINAVIR; MICE; SIGNAL TRANSDUCTION; TRETINOIN; VITAMIN A;

EID: 0033954636     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00246-X     Document Type: Article

References (33)

1. Danner S.A., Carr A., Leonard J.M., Lehman L.M., Gudiol F., Gonzales J., Raventos A., Rubio R., Bouza E., Pintado A., Aguado A.G., Garcia de Lomas J., Delgado R., Borleffs J., Hsu A., Valdes J., Boucher C., Cooper D.A. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med. 333:1995;1528-1533.
2. Sullivan A.K., Nelson M.R. Marked hyperlipidemia on ritonavir therapy. AIDS. 11:1997;938-939.
3. Massip P., Marchou B., Bonnet E., Cuzin L., Montastruc J.L. Lipodystrophia with protease inhibitors in HIV patients. Therapie. 52:1997;615.
4. Miller K.D., Jones E., Yanovski J.A., Shankar R., Feuerstein I., Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 351:1998;871-875.
5. Behrens G., Schmidt H., Meyer D., Stoll M., Schmidt R.E. Vascular complications associated with use of HIV protease inhibitors. Lancet. 351:1998;1958.
6. Carr A., Samaras K., Burton S., Law M., Freund J., Chisholm D.J., Cooper D.A. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 12:1998;F51-F58.
7. Lo J.C., Mulligan K., Tai V.W., Algren H., Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet. 351:1998;867-870.
8. Viraben R., Aquilina C. Indinavir-associated lipodystrophy. AIDS. 12:1998;F37-F39.
9. Walli R., Herfort O., Michl G.M., Demant T., Jager H., Dieterle C., Bogner J.R., Landgraf R., Goebel F.D. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients. AIDS. 12:1998;F167-F173.
10. Carr A., Samaras K., Chisholm D.J., Cooper D.A. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 351:1998;1881-1883.
11. Mocroft A., Vella S., Benfield T.L., Chiesi A., Miller V., Gargalianos P., d'Arminio Monforte A., Yust I., Bruun J.N., Phillips A.N., Lundgren J.D. for the EuroSIDA Study Group, Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet. 352:1998;1725-1730.
12. Madge S., Kinloch-de-Loes S., Mercey D., Johnson M.A., Weller I.V. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS. 13:1999;735-737.
13. Hadigan C., Miller K., Corcoran C., Anderson E., Basgoz N., Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 84:1999;1932-1937.
14. Grunfeld C., Kotler D.P., Shigenaga J.K., Doerrler W., Tierney A., Wang J., Pierson R.N. Jr, Feingold K.R. Circulating interferon-α levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 90:1991;154-162.
15. Vahlquist A. Long-term safety of retinoid therapy. J Am Acad Dermatol. 27:1992;S29-S33.
16. Ribalta J., Girona J., Vallvé J.C., La Ville A.E., Heras M., Masana L. Vitamin A is linked to the expression of the AI-CIII-AIV gene cluster in familial combined hyperlipidemia. J Lipid Res. 40:1999;426-431.
17. Standeven A.M., Beard R.L., Johnson A.T., Boehm M.F., Escobar M., Heyman R.A., Chandraratna R.A. Retinoid-induced hypertriglyceridemia in rats is mediated by retinoic acid receptors. Fundam Appl Toxicol. 33:1996;264-271.
18. Kuri-Harcuch W. Differentiation of 3T3-F442A cells into adipocytes is inhibited by retinoic acid. Differentiation. 23:1982;164-169.
19. Paulik M.A., Lenhard J.M. Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells. Cell Tissue Res. 290:1997;79-87.
20. Johnson A.T., Klein E.S., Gillett S.J., Wang L., Song T.K., Pino M.E., Chandraratna R.A. Synthesis and characterization of a highly potent and effective antagonist of retinoic acid receptors. J Med Chem. 38:1995;4764-4767.
21. Shudo K., Kagechika H. Structural evolution of retinoids. Adv Drug Res. 24:1993;80-118.
22. Boehm M.F., Zhang L., Badea B.A., White S.K., Mais D.E., Berger E., Suto C.M., Goldman M.E., Heyman R.A. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J Med Chem. 38:1995;3146-3155.
23. Bouscarat F., Bouchard C., Bouhour D. Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir. N Engl J Med. 338:1998;1776-1777.
24. Katayama H., Okabe N., Kano T., Yaoita H. Granulation tissue that developed after a minor trauma in a psoriatic patient on long-term etretinate therapy. J Dermatol. 17:1990;187-190.
25. Kakuda T.N., Struble K.A., Piscitelli S.C. Protease inhibitors for the treatment of human immunodeficiency virus infection. Am J Health Syst Pharm. 55:1998;233-254.
26. Gold E.J., Mertelsmann R.H., Itri L.M., Gee T., Arlin Z., Kempin S., Clarkson B., Moore M.A.S. Phase I clinical trial of 13-cis-retinoic acid in myelodysplastic syndromes. Cancer Treat Rep. 67:1983;981-986.
27. Padberg J., Schurmann D., Grobusch M., Bergmann F. Drug interaction of isotretinoin and protease inhibitors Support for the cellular retinoic acid-binding protein-1 theory of lipodystrophy? AIDS. 13:1999;284-285.
28. Bouscarat F., Prevot M.H., Matheron S. Alopecia associated with indinavir therapy. N Engl J Med. 341:1999;618.
29. Lenhard J.M., Kliewer S.A., Paulik M.A., Plunket K.D., Lehmann J.M., Weiel J.E. Effects of troglitazone and metformin on glucose and lipid metabolism Alterations of two distinct molecular pathways . Biochem Pharmacol. 54:1997;801-808.
30. Kenakin T, Lenhard JM and Paulik MA, β-Adrenoceptor assays. In: Current Protocols in Pharmacology (Eds. Enna SJ, Williams M, Ferkany JW, Kenakin T, Porsolt RD and Sullivan JP), pp. 4.6.1-4.6.36. John Wiley, New York, 1998.
31. Norris A.W., Cheng L., Giguere V., Rosenberger M., Li E. Measurement of subnanomolar retinoic acid binding affinities for cellular retinoic acid binding proteins by fluorometric titration. Biochim Biophys Acta. 1209:1994;10-18.
32. Lenhard J., Furfine E., Paulik M., Croom D., Spaltenstein A., Weiel J. Effect of HIV-protease inhibitors on in vitro adipogenesis and in vivo fat deposition. Antiviral Ther. 4:(Suppl 2):1999;3.
33. Balani S.K., Woolf E.J., Hoagland V.L., Sturgill M.G., Deutsch P.J., Yeh K.C., Lin J.H. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab Dispos. 24:1996;1389-1394.